Rarity Bioscience

Rarity Bioscience is a Swedish biotechnology company founded in 2021 and based in Uppsala. It develops ultra-sensitive mutation detection technologies for cancer diagnostics and precision medicine. The company's work sits at the intersection of molecular diagnostics, DNA analysis and clinical decision-making, where the ability to identify rare genetic variants determines what information can be drawn from a sample.

Its core offering is the superRCA® technology platform, a proprietary system engineered to detect rare mutations at very high sensitivity. According to the company, the platform resolves a single mutation among 100,000 wild-type DNA molecules - a ratio relevant to applications in which mutant DNA is diluted by large quantities of normal DNA, as is typical in circulating tumour DNA analysis and other forms of liquid biopsy work.

The company employs approximately 30 scientists and professionals. It describes its working environment as collaborative and cross-functional, with an open culture, short lines between questions and decisions, and contributions that are visible across the team.